Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
New pamphlet on the NIF mouse as a liver fibrosis model
Read our new pamphlet on the NIF mouse as a model for studies of liver fibrosis. The NIF mouse can be used both as a model for tests of drugs to treat general liver fibrosis, [...]
InfiCure Bio received a seal of excellence from EU
The application to Horizon 2020 SME Instrument Phase II submitted by InfiCure Bio i January 2019 was awarded a seal of excellence. This means that the application passed the score set by EU for grant [...]
InfiCure Bio will present at Keystone Symposium in January 2019
Julia Nilsson, Research Associate at InfiCure Bio, will be presenting at the Keystone Symposium: "Integrated Pathways of Disease in NASH and NAFLD" in Santa Fee January 20-24 2019. Julia will present new data on the [...]
Anti-Fibrotic Drug Development Summit
The CEO of InfiCure Bio was one of 28 Expert Speakers at the Anti-Fibrotic Drug Development Summit held in Boston November 27-29 2018. InfiCure Bio was presenting new data on the unique NIF mouse as [...]